Protagonist Therapeutics, Inc. logo PTGX - Protagonist Therapeutics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 25
HOLD 1
SELL 0
STRONG
SELL 0
| PRICE TARGET: $123.25 DETAILS
HIGH: $145.00
LOW: $110.00
MEDIAN: $119.00
CONSENSUS: $123.25
DOWNSIDE: 6.22%

Stock News

Protagonist Therapeutics Reports Granting of Inducement Awards

Protagonist Therapeutics Reports Granting of Inducement Awards

NEWARK, CA / ACCESS Newswire / July 1, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on June 30, 2026, it granted inducement awards to three recently hired employees in accordance with the terms of their employment offer letters. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.

Jul 01, 2026 12:05 PM • accessnewswire.com
Protagonist Therapeutics Reports Granting of Inducement Awards

Protagonist Therapeutics Reports Granting of Inducement Awards

NEWARK, CA / ACCESS Newswire / June 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on June 15, 2026, it granted inducement awards to three recently hired employees in accordance with the terms of their employment offer letters. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.

Jun 16, 2026 12:00 PM • accessnewswire.com
Protagonist Therapeutics: A Royalty-Driven Biotech With Two Shots On Goal

Protagonist Therapeutics: A Royalty-Driven Biotech With Two Shots On Goal

Protagonist Therapeutics (PTGX) has transitioned from binary clinical risk to execution risk, leveraging major pharma partners for commercialization without heavy infrastructure costs. ICOTYDE's FDA approval and rusfertide's Priority Review position PTGX for milestone payments, high-margin royalties, and a capital-light revenue model. PTGX maintains a strong balance sheet with $620M+ cash, a funding runway through 2028, and episodic profitability, reducing financing risk.

Jun 13, 2026 04:46 AM • seekingalpha.com
Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress

Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress

NEWARK, CA / ACCESS Newswire / June 1, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that four abstracts highlighting rusfertide in polycythemia vera (PV) will be presented at the 2026 European Hematology Association Congress (EHA2026 Congress), taking place June 11-14, 2026, in Stockholm, Sweden. The presentations include analyses from the randomized, controlled Phase 3 VERIFY study, as well as long-term results from the Phase 2 REVIVE and THRIVE open-label extension studies.

Jun 01, 2026 03:05 AM • accessnewswire.com
Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update

Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update

ICOTYDE™ (icotrokinra) approved by FDA in March for moderate-to-severe plaque psoriasis, triggering a $50 million milestone payment; Protagonist receives tiered royalties of 6% to 10% and is eligible for up to $580 million in future milestone payments Rusfertide NDA accepted and granted Priority Review by FDA, with a Prescription Drug User Fee Act target action date in the third quarter of 2026 Protagonist exercised its rusfertide opt-out right under the Takeda collaboration on April 28, triggering a $200 million opt-out fee payable to the Company; eligible for additional $200 million opt-out and $75 million milestone payments upon NDA approval, sales milestones of up to $775 million and worldwide royalties ranging from 14% to 29% PN-881 (oral IL-17 antagonist peptide) Phase 1 study completion by mid-2026 and Phase 2 initiation anticipated by year-end; PN-477sc and PN-477o (sc and oral triple GLP/GIP/GICG agonist) Phase 1 initiation expected in mid-2026 and Q1 2027, respectively Cash, cash equivalents and marketable securities of $620 million as of March 31, 2026, anticipated to provide cash runway through at least 2028 NEWARK, CA / ACCESS Newswire / May 5, 2026 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. "The first quarter of 2026 marked a series of landmark achievements for Protagonist, highlighted by the U.S. approval of ICOTYDE, FDA granting Priority Review for rusfertide, and advancement of our highly differentiated and fully-owned peptides PN-881 and PN-477," said Dinesh V.

May 05, 2026 12:05 PM • accessnewswire.com
Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration

Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration

Opt-out election makes Protagonist eligible for $200 million upon exercise and an additional $200 million upon FDA approval of rusfertide for polycythemia vera Approval would also trigger a $75 million milestone payment, bringing total potential cash tied to the opt-out election and approval to $475 million Protagonist becomes eligible for up to $975 million in milestone payments and tiered royalties ranging from 14% to 29% on worldwide net sales NEWARK, CA / ACCESS Newswire / April 28, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) ("Protagonist" or the "Company") today announced that it has exercised its right to opt out of the 50:50 U.S. profit and loss sharing arrangement under its worldwide license and collaboration agreement with Takeda for rusfertide, an investigational first-in-class hepcidin mimetic peptide under U.S. Food and Drug Administration (FDA) Priority Review for the treatment of adults with polycythemia vera (PV). By exercising its opt-out right during the contractual opt-out period, Protagonist becomes eligible to receive up to $400 million in opt-out payments, consisting of $200 million payable upon the opt-out election and a further $200 million payable upon FDA approval of rusfertide for the treatment of adults with PV.

Apr 28, 2026 05:05 AM • accessnewswire.com
Protagonist Therapeutics Reports Granting of Inducement Awards

Protagonist Therapeutics Reports Granting of Inducement Awards

NEWARK, CA / ACCESS Newswire / April 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on April 15, 2026, it issued inducement awards to two recently hired employees in accordance with the terms of their employment offer letters. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.

Apr 16, 2026 12:05 PM • accessnewswire.com
Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting

Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting

One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once daily pill for moderate-to-severe plaque psoriasis Results further support the differentiated profile of ICOTYDE, the first and only IL-23 receptor targeted oral peptide NEWARK, CA / ACCESS Newswire / March 28, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) ("Protagonist" or "the Company") today announced new one-year Phase 3 results for ICOTYDE™ (icotrokinra) were presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting. Data from the Phase 3 ICONIC-ADVANCE 1 and 2 and ICONIC-LEAD studies further support the potential of ICOTYDE as a differentiated oral therapy for patients with moderate-to-severe plaque psoriasis.

Mar 28, 2026 06:05 AM • accessnewswire.com
Protagonist Partners With Johnson & Johnson To Compete With AbbVie's Skyrizi

Protagonist Partners With Johnson & Johnson To Compete With AbbVie's Skyrizi

Protagonist Therapeutics earns a Buy rating, driven by Icotyde's FDA approval and robust near-term commercialization catalysts. Icotyde, the first oral IL-23 receptor antagonist for plaque psoriasis, offers best-in-class oral efficacy and placebo-like safety, with significant royalty and milestone potential. PTGX's pipeline, validated by Icotyde and Rusfertide, leverages its proprietary Vectrix platform to target obesity, hematology, and inflammation, supporting long-term value creation.

Mar 24, 2026 04:45 AM • seekingalpha.com
Protagonist Therapeutics Soars as FDA Approves ICOTYDE for Plaque Psoriasis, Triggers $50M Milestone

Protagonist Therapeutics Soars as FDA Approves ICOTYDE for Plaque Psoriasis, Triggers $50M Milestone

Protagonist Therapeutics (NASDAQ: PTGX) executives said March 18 that the U.S. Food and Drug Administration has approved ICOTYDE for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kilograms and are candidates for systemic therapy or phototherapy. On the company's conference call, President

Mar 22, 2026 10:02 PM • defenseworld.net

Price Targets